Biotech Analyst Battle: Arcus Biosciences Faces Conflicting Outlooks

Arcus Biosciences finds itself at the center of a sharp Wall Street divide. The biopharmaceutical company is receiving dramatically different assessments from financial analysts, creating a clear bull-versus-bear scenario for investors. While Wells Fargo has boosted its price target significantly, Weiss Ratings maintains a starkly pessimistic stance, even as the company announces substantial progress in its oncology pipeline.

Financial Backing and Upcoming Triggers

The company enters this period of conflicting analyst opinions from a position of financial strength. Arcus Biosciences maintains a substantial war chest exceeding $900 million, providing ample funding for its late-stage clinical programs through their critical readouts. Demonstrating its financial momentum, the company’s second-quarter revenue reached $160 million, dramatically surpassing expectations by fivefold.

• Next Financial Report: Third-quarter results are scheduled for November 5.
• Consensus Price Target: The average analyst price target sits at $27.22, implying a potential 57% upside.
• Technical Position: The 50-day moving average, positioned at $11.41, continues to signal a positive intermediate-term trend.

The shares recently traded at $17.32, extending a recent upward movement with a 3.2% gain. The coming weeks will determine whether the optimistic or cautious voices prevail.

A Clash of Analyst Convictions

The disagreement among market experts is pronounced. Weiss Ratings recently confirmed its “Sell (D-)” recommendation for Arcus, presenting a notably gloomy view that contrasts with the prevailing sentiment. This “Sell” rating stands in direct opposition to the “Buy” recommendations currently held by eight other covering banks.

The contrast becomes even starker when looking at Wells Fargo. The prominent investment bank not only reaffirmed its “Overweight” rating but also raised its price target from $25 to $29 per share, signaling strong conviction in the company’s future performance.

Should investors sell immediately? Or is it worth buying Arcus Biosciences?

Strategic Expansion and Clinical Progress

Beyond the analyst debate, Arcus continues to execute its business development and clinical strategy. A significant achievement was announced over the weekend: Taiho Pharmaceutical secured an exclusive license for the drug candidate casdatifan in Japan and several other Asian markets. This marks the fifth option exercised by Taiho, underscoring a robust and trusting collaborative partnership between the two firms.

Casdatifan, a HIF-2α inhibitor, is currently undergoing a global Phase 3 trial for renal cell carcinoma. The licensing agreement provides Arcus with an optional exercise payment and positions the company to receive further milestone payments tied to clinical, regulatory, and commercial successes.

The company’s clinical momentum extends to other areas. At the ESMO 2025 conference, Arcus presented encouraging initial overall survival data from its Phase 2 EDGE-Gastric study for advanced gastric cancer. The combination of domvanalimab, zimberelimab, and chemotherapy demonstrated promising efficacy, forming the foundation for the ongoing Phase 3 trial known as STAR-221.

Earlier in October, the company also released updated monotherapy data for casdatifan and unveiled five new research programs targeting autoimmune diseases, signaling a strategic expansion of its pipeline beyond oncology.

The long-term trajectory of Arcus Biosciences will be heavily influenced by the outcomes of its Phase 3 trials for casdatifan, domvanalimab, and quemliclustat, with key data expected in 2026.